29166

We are a new oncology therapeutics company working on developing lead candidates that reformulate drugs like Bortezomib. Currently, we are at the preclinical stage and aim to move our lead candidates to clinical trials within 18 months. We were hoping to negotiate large purchases of GMP-grade Bortezomib if available. Please let us know if this opportunity is of interest.